Division of Neurology, Department of Medicine, National Core for Neuroethics, University of British Columbia, Vancouver, British Columbia, Canada.
BMC Psychiatry. 2013 Aug 8;13:208. doi: 10.1186/1471-244X-13-208.
Functional neuroimaging is being used in clinical psychiatry today despite the vigorous objections of many in the research community over issues of readiness. To date, a systematic examination of the perspectives of key stakeholders involved in this debate has not yet been attempted. To this fill this gap, we interviewed investigators who conduct functional neuroimaging studies involving adults with mood disorders, schizophrenia, obsessive compulsive disorder, and/or attention deficit hyperactivity disorder, providers who offer clinical neuroimaging services in the open marketplace, and consumers of these services, in order to understand perspectives underlying different views and practices.
Semi-structured interviews were conducted over the telephone. Verbal consent was obtained and all interviews were audio recorded. Interviews of investigators and service providers followed the same interview guide. A separate set of questions was developed for consumers. All interviews were transcribed and made software ready. We applied the qualitative methodology of constant comparison to analyze the data, whereby two researchers independently analyzed the results into textual themes. Coding discrepancies were discussed until consensus was achieved.
Investigators, service providers, and consumers held many common perspectives about the potential or actual risks and benefits of functional neuroimaging for mental illness. However, we also found striking divergences. Service providers focused on the challenges posed by the persistence of symptoms based diagnostic categories, whereas the limitations of the science in this area was the challenge noted most frequently by investigators. The majority of consumers stated that their expectations were met.
Our findings point toward a fundamental tension between academic investigators on the one hand, and commercial service providers and their customers on the other. This scenario poses dangers to the communities directly involved, and to public trust in science and medicine more generally. We conclude with recommendations for work that needs to be done to minimize tensions and maximize the potential of neurotechnology through concerted efforts to respect its limitations while leveraging the strengths, investments, and hopes of each stakeholder group.
尽管研究界的许多人对准备情况存在强烈反对,但功能神经影像学今天仍在临床精神病学中得到应用。迄今为止,尚未尝试系统地检查参与这场辩论的主要利益相关者的观点。为了填补这一空白,我们采访了从事涉及成人情绪障碍、精神分裂症、强迫症和/或注意力缺陷多动障碍的功能神经影像学研究的研究人员、在公开市场提供临床神经影像学服务的服务提供者以及这些服务的消费者,以了解不同观点和做法背后的观点。
通过电话进行半结构化访谈。获得口头同意,并对所有访谈进行录音。对研究人员和服务提供者的访谈遵循相同的访谈指南。为消费者制定了一套单独的问题。所有访谈都进行了转录并准备好软件。我们应用了不断比较的定性方法来分析数据,其中两名研究人员将结果独立分析为文本主题。讨论编码差异,直到达成共识。
研究人员、服务提供者和消费者对功能神经影像学对精神疾病的潜在或实际风险和益处持有许多共同的观点。然而,我们也发现了惊人的分歧。服务提供者关注基于症状持续存在的诊断类别所带来的挑战,而该领域科学的局限性是研究人员最常提到的挑战。大多数消费者表示他们的期望得到了满足。
我们的研究结果表明,学术研究人员一方面与商业服务提供商及其客户之间存在根本紧张关系。这种情况对直接相关的社区以及对公众对科学和医学的信任构成了危险。我们的结论是,需要通过共同努力来最小化紧张局势并最大限度地发挥神经技术的潜力,这些努力需要尊重其局限性,同时利用每个利益相关者群体的优势、投资和希望。